ORIGINAL ARTICLE |
|
Year : 2018 | Volume
: 12
| Issue : 4 | Page : 386-390 |
|
Serum adiponectin as a biomarker for chronic obstructive pulmonary disease and lung cancer and its relation to severity
Amany T Gayed1, Riham H Raafat2
1 Chest Departement, Ainshams University, Cairo, Egypt 2 Ainshams University Hospitals, Cairo, Egypt
Correspondence Address:
Riham H Raafat 8th Mahdy Ebn Baraka Street, District 7, Nasr City, Cairo, 11765 Egypt
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/ejb.ejb_22_18
|
|
Introduction ‘Chronic obstructive pulmonary disease’ (COPD) is an inflammatory disorder associated with airway narrowing and airflow limitation in response to air pollution, gases, and smoking and is associated with morbidity and mortality. Cancer is also considered as a systemic inflammatory disorder where pro-inflammatory cytokines and mediators are released.
Aim To evaluate serum adiponectin level in COPD and lung cancer and its importance in detecting and predicting severity.
Patients and methods A total of 40 patients were recruited in the study: 20 had stable COPD and 20 had lung cancer. Moreover, another 10 age-matched and sex-matched individuals were included as a control group. All were subjected to routine laboratory chest radiography, spirometry, and serum adiponectin level measurement.
Results The results showed an increase of adiponectin level in both patients with COPD and those with lung cancer, and significant correlation was found between adiponectin level and forced expiratory volume in 1 s and performance status.
Conclusion Adiponectin serum level is elevated in both COPD and lung cancer and significantly elevated in severe cases. |
|
|
|
[FULL TEXT] [PDF]* |
|
|
|